Webinar Presentation
3rd Quarter and 9 months of 2018

December 6, 2018
3rd Quarter
Sales in 3rd Quarter

- One of the best third quarters in corporate history;
- After adjusted results, sales in this Q3 are smaller by 4k EUR than sales made in Q3 2017;
- Sales worth more than 27.6 million euros;
- Sales by pharmacies = 5.6 million gross, 3 million net;
- Sales by Silvanols = 1.2 million gross, 0.9 million net;
- Sales by Tonus Elast and Elast Medical = 2.2 million net.

www.olainfarm.com
Profit of 3rd Quarter

- Preliminary at 1.7 million euros, an increase by almost 86% compared to Q3 217;
- Smaller write offs (by about 1.1 mln) offset bigger (by about 0.2 mln) forex losses;
- Gross profit slightly larger despite slightly lower sales, meaning higher margin sales mix;

www.olainfarm.com
12 months EBITDA increased to 17.8 million EUR, while margin increased to 15%;

Both, EBITDA and margin are recovering as Q3 2018 with 1.1 million assets write offs are leaving TTM;

Forex loss (deriving mainly from receivables) does not influence EBITDA;
Sales by Products, 3rd Quarter

- Compared to Q2 Neiromidin and Noofen switched positions;
- Some sales recovery to PASA and Remantadin, as flu season approaches, thus they both replaced Memantine and Meldonium;
- All others relatively stable
Sales by Countries, 3rd Quarter

- Compared to Q2, Russia’s lead a little greater as sales to Russia slightly recovered;

- Belarus lost 2pp, Ukraine 4pp, The Netherlands returned as PASA sales recovered;

- Uzbekistan and Lithuania replaced by The Netherlands and Kyrgyzstan.
9 Months
Sales in 9 Months

- Sales worth slightly less than 90 million euros;
- A reduction by less than 1% compared to 9M 2017, mainly due to very good sales of PASA to WHO throughout 2017;
- Sales by pharmacies = 17.3 million gross, 7.7 million net;
- Sales by Silvanols = 4.1 million gross, 3 million net;
- Sales by Tonus Elast and Elast Medical = 7.1 million net.
Profit in 9 Months

- Preliminary at 7.5 million euros, an increase by 13% compared to 9M 217;
- Better sales mix, less asset write offs are the main contributors;
- Small positive impact of changes to Latvian tax legislation.

Net Earnings, 9 Months, Thsnd. EUR
Growth Drivers: Products

- 9 out of 15 growing;
- Most growth in monetary terms added by Noofen (0.8 m) and Etacizin (0.5 m);
- Most growth in relative terms provided by R(-) Quinuclidinol (215%) and Memantine (64%);
- Most loss in monetary terms comes from PASA (-3.3 m) and Adaptol (-0.7 m);
- Most loss in relative terms also comes from PASA others (-84%) and Remantadin (-64%);
Growth Drivers: Countries

- 11 out of 15 growing;
- Most growth in monetary terms added by Belarus (3.3 m) and Latvia (3.8 m);
- Most growth in relative terms provided by Japan (322%) and Tajikistan (64%);
- Most loss in monetary terms comes from The Netherlands (-3.2 m) and Russia (-2 m);
- Most loss in relative terms also comes from The Netherlands (-84%) and Italy (-23%).
Poll Question
Update on Recent Events
Annual Baltic Sea Roadshow Completed

- Six countries and seven cities covered in two weeks;
- In total more than 30 meetings, up to five company representatives attending;
- Very considerable interest, in some cities as many as seven meetings were held.
Poll Question
EGM on November 22nd, 2018

- Initially convened by two minority shareholders;
- Among other things, changes to Council and Articles were proposed;
- All of the proposed decisions were rejected by a very considerable majority of votes;
Poll Question
Disclaimer

This Presentation has been drawn up by AS Olainfarm (‘The Company’) purely for informational and marketing purposes. It may not, without the prior consent of the Company, be reproduced or used for any other purpose. This Presentation is not advising nor soliciting any action based upon it.

The information made available in this Presentation has been chosen and provided by the Company at its sole discretion and it is not aiming to be exhaustive or complete. Although every effort is made to ensure that the information contained in this Presentation is correct and not misleading, the Company assumes no liability of whatever nature for the correctness, comprehensiveness or completeness of the information contained herein.

This Presentation or any piece of information may not be construed as a representation or warranty of the Company or any other person.

This document contains forward-looking statements that are based on the Company’s expectations, estimates, projections and assumptions. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contemplated by such statements. Forward-looking statements are made and based on information available to the Company on the date of this document. The Company does not assume, and expressly disclaims, any obligation to update this information, nor does the Company take any responsibility to guarantee any result predicted in this document to become actual.

www.olainfarm.com
Q&A Session